[A20-78] Secukinumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V

Last updated 18.02.2021

Project no.:
A20-78

Commission:
Commission awarded on 31.08.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Skin and hair

Indication:

Children and adolescents from the age of 6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy

Result of dossier assessment:

Added benefit not proven due to lack of suitable study data

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2021-0218: A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form